Computerized Systems • Pharmaceutical Quality • Risk-Based Assurance
Computer Software Assurance (CSA) vs CSV
Understand how Computer Software Assurance (CSA) differs from Computerized System Validation (CSV), where FDA’s CSA guidance applies, and how pharmaceutical teams can use risk-based assurance while meeting applicable GMP requirements.
%20vs%20CSV%20(1).webp "Computer Software Assurance (CSA) vs CSV")
Computer Software Assurance (CSA) and Computerized System Validation (CSV) share a practical goal: build documented confidence that software is reliable and fit for its intended use. The terms are related, but they are not interchangeable. CSV describes the broader validation lifecycle commonly used for pharmaceutical GxP computerized systems. CSA is the risk-based approach set out in FDA guidance for software used in medical-device production and quality management systems. Pharma organizations may adopt CSA-style critical thinking to focus assurance on meaningful risk, but that does not automatically replace applicable drug GMP, electronic-record, or site quality-system requirements.
No. FDA’s current CSA guidance is scoped to medical-device production and quality-management-system software. In pharmaceutical operations, companies remain responsible for demonstrating that GxP systems are fit for intended use and controlled through their lifecycle. Risk-based assurance can make CSV more focused, but it does not waive applicable requirements such as drug GMP controls, record retention, or Part 11 controls when those rules apply.
What Is Computerized System Validation (CSV)?
Computerized System Validation is the documented lifecycle work used to show that a computerized system consistently performs as intended in its regulated context. The system may be a configurable commercial application, a custom application, a laboratory instrument with software, a manufacturing control platform, a cloud service, or an interface connecting multiple systems.
In pharma, CSV begins with understanding the process and intended use—not with choosing a template. Teams define system boundaries, requirements, risks, configuration, verification, release conditions, operating controls, and retirement plans. The scale of work should reflect the system’s GxP impact, complexity, novelty, supplier evidence, and the consequences of failure. A documented computerized system validation lifecycle links those decisions to evidence.
CSV is not one fixed packet of documents or a requirement to test every screen in the same way. It is a controlled, justified approach for establishing and maintaining fitness for intended use under applicable cGMP and quality-system requirements.
What Is Computer Software Assurance (CSA)?
CSA is a risk-based approach for establishing confidence that software is fit for its intended use. FDA’s current final guidance, issued on February 3, 2026, is titled Computer Software Assurance for Production and Quality Management System Software. FDA describes the approach for computers and automated data-processing systems used as part of medical-device production or the quality management system. The 2026 document supersedes the earlier September 2025 final version and is explicitly presented as nonbinding guidance.
The guidance encourages teams to consider intended use, risk, appropriate assurance activities, changes, and the records needed to support a conclusion. Depending on risk, examples of assurance activities include robust scripted testing, limited scripted testing, unscripted scenario testing, error-guessing, and exploratory testing. “Unscripted” does not mean unplanned or undocumented: the organization still needs a clear purpose, appropriate controls, recorded results, issue handling, and a reasoned conclusion.
Because FDA identifies the scope as medical-device production and QMS software, pharmaceutical companies should not cite the CSA guidance as if it were a blanket replacement for drug CGMP requirements. They can use its risk-based concepts where suitable, while retaining a documented assessment against the rules and commitments that govern their pharmaceutical activities.
CSA vs CSV: The Main Differences
| Comparison point | CSV | CSA |
|---|---|---|
| Meaning | A lifecycle approach for validating computerized systems used in regulated processes. | A risk-based approach for establishing confidence in software for its intended use. |
| Regulatory context | Applied within relevant pharmaceutical GMP and electronic-record obligations, along with company procedures. | FDA guidance scope is medical-device production and quality-management-system software. |
| Primary emphasis | System lifecycle, requirements, risk controls, verification, release, and ongoing control. | Right-sized assurance activities based on intended use and risk, with emphasis on useful objective evidence. |
| Testing options | May use scripted, unscripted, manual, automated, supplier, and site-specific evidence as justified. | FDA guidance describes a range of scripted and unscripted testing approaches for its stated scope. |
| Documentation | Records show scope, rationale, requirements, verification, deviations, approvals, and operational controls as appropriate. | Evidence is proportionate to risk; records still support what was tested, results, issues, tester/date, and acceptability. |
| Relationship | Provides the wider lifecycle structure used by many pharma quality systems. | Can inform a more focused assurance strategy; it is not a separate exemption from pharma requirements. |
The table is a practical comparison, not a regulatory equivalence statement. A site should define terminology in its quality procedures so that “CSA,” “CSV,” “validation,” and “assurance” are used consistently.
Why the Regulatory Scope Matters for Pharmaceutical Companies
FDA’s CSA guidance was prepared for medical-device production and quality-management-system software and discusses obligations under the device quality-management framework. Pharmaceutical systems are assessed under the drug GMP rules that apply to their use. In the United States, requirements may include 21 CFR Part 211 provisions for equipment, records, laboratory data, and batch decisions. 21 CFR requirements should be assessed by record type, process, and intended use.
Part 11 is relevant when electronic records are used to satisfy applicable FDA record requirements or when electronic signatures are used in the covered context. FDA’s scope guidance explains the connection to predicate rules; it does not mean every electronic file automatically falls within Part 11. The actual record, applicable predicate requirement, and way the organization relies on the record matter. The regulation remains in effect, so a risk-based validation strategy is not a waiver.
For EU GMP operations, Annex 11 addresses computerized systems. The European Commission’s currently published EudraLex Volume 4 page lists Annex 11 as “Computerised Systems” and identifies its current published revision as January 2011. Sites should verify the applicable version and any formally adopted updates for the markets in which they operate.
Data governance and ALCOA+ data integrity principles remain central. A system can pass functional tests yet still be unsuitable if users can alter records without traceability, critical data are lost during transfer, or retained records cannot be retrieved for review or inspection.
How Pharma Teams Can Apply CSA Principles Within CSV
Use CSA-style thinking to focus the validation effort, while keeping the regulatory basis and lifecycle controls clear. A practical process is:
- Define intended use and boundaries. Describe the GxP process, functions, users, interfaces, data flows, records, and decisions supported. Separate regulated functions from unrelated features where justified.
- Assess impact and risk. Consider how software failure could affect patient safety, product quality, process control, record completeness, or a quality decision. Evaluate detectability and existing procedural or technical controls.
- Write testable requirements. Translate process needs into verifiable statements. Include calculations, limits, permissions, audit trails, electronic signatures, interfaces, backup, restore, retention, and reporting when relevant. A well-defined URS supports traceability.
- Evaluate supplier and service-provider evidence. Review what the supplier actually tested, the version and configuration covered, relevant deviations, security controls, release practices, and the evidence available. Supplier documents can reduce duplicate work when they are applicable and credible; they do not transfer the regulated firm’s responsibility.
- Choose assurance activities by risk. Use repeatable scripted tests for high-impact or complex functions where precise expected results matter. Consider scenario-based or exploratory testing for suitable lower-risk functions, with a defined objective and recorded outcome. Do not use “unscripted” as a synonym for undocumented.
- Resolve issues and make a release decision. Record failures, assess their impact, correct or justify them, retest as needed, and approve the system for the defined use only when acceptance criteria are met.
- Maintain the validated state. Control access, training, procedures, changes, incidents, backup and restoration, periodic review, supplier releases, archival, and retirement.
Practical example: a LIMS calculation used for batch release
Suppose a laboratory information management system calculates an assay result used by Quality to make a batch disposition decision. The risk assessment should consider formula selection, rounding, units, specification limits, user permissions, audit-trail behavior, instrument data transfer, and handling of invalid or missing inputs. The team may use supplier testing for standard platform functions, then perform site-specific verification of the configured calculation and workflow using normal, boundary, and challenge cases. The release record should identify the tested configuration, results, deviations, and the conclusion that the function is acceptable for its intended use.
If the same application also includes a display-only dashboard that is not used to make or justify a GMP decision, it may warrant a different level of assurance. The intended use—not the product name—drives the assessment.
What Evidence Should the Validation or Assurance Record Contain?
Documentation should be sufficient for a knowledgeable reviewer to understand what was assured, why the approach was appropriate, and whether the system is acceptable for its intended use. Depending on risk and the company procedure, the record set may include:
- GxP impact assessment, system boundary, intended use, and accountable owners.
- Risk assessment tied to specific functions, failure modes, and controls.
- Requirements and traceability to configuration, testing, and acceptance.
- Supplier qualification and review of supplier test evidence.
- Test objectives, test methods, expected outcomes where used, actual results, and relevant digital evidence.
- Issues, deviations, impact assessments, corrections, retest results, and approvals.
- Assessment of electronic records, signatures, audit trails, retention, and retrieval where applicable.
- Release authorization, procedures, training, access controls, change control, and ongoing monitoring.
Keep records attributable, readable, contemporaneous, original or verified true copies, accurate, complete, consistent, enduring, and available. Your site SOPs should state how risk is assessed, when supplier evidence may be leveraged, which test approaches are acceptable, and how decisions are approved.
Common CSA and CSV Misunderstandings
- “CSA replaces CSV in every industry.” It does not. The FDA guidance has a defined device production/QMS software scope.
- “CSA means less testing.” It means effort should be proportionate to risk. High-impact functions can require more rigorous testing, not less.
- “Unscripted testing needs no record.” Testing still needs an objective, results, issue handling, and a conclusion appropriate to its use.
- “A vendor’s validation certificate is enough.” The customer must assess supplier evidence and validate the configured system for its own intended use.
- “Part 11 applies to every digital file.” Determine applicability based on records required by predicate rules, submissions, and how records/signatures are used.
- “A passed test proves the whole system is compliant.” Compliance also depends on procedures, training, security, records, operation, change control, and continued oversight.
CSA and CSV Readiness Checklist
- System is inventoried and its GxP impact decision is approved.
- Intended use, users, boundaries, data flows, and interfaces are described.
- Pharmaceutical regulatory scope is assessed separately from device-only guidance.
- Requirements are testable and linked to risks and controls.
- Supplier evidence is reviewed for relevance, version, configuration, and quality.
- Assurance activities match the impact and uncertainty of each critical function.
- Electronic records, signatures, audit trails, retention, and retrieval are assessed.
- Test failures and deviations have documented resolution or justified disposition.
- Release approval, training, access, and procedures are effective.
- Changes, incidents, periodic review, backup, restore, and retirement are controlled.
Frequently Asked Questions
Is CSA the same as CSV?
No. CSV is the broader lifecycle validation approach used for computerized systems in regulated processes. CSA is a risk-based software assurance approach described in FDA guidance for medical-device production and QMS software.
Does the FDA CSA guidance apply to pharmaceutical manufacturing?
The current FDA CSA guidance is specifically scoped to medical-device production and quality-management-system software. Pharmaceutical firms can consider its risk-based concepts, but should not treat it as a replacement for drug GMP requirements.
What is the current FDA CSA guidance?
FDA issued “Computer Software Assurance for Production and Quality Management System Software” on February 3, 2026. It superseded the September 24, 2025 final guidance and remains nonbinding guidance.
Does CSA eliminate validation documentation?
No. The amount and form of evidence may be scaled to risk, but the organization still needs records that support intended use, risk analysis, assurance activities, results, issue disposition, tester and date, and an acceptability conclusion as appropriate.
Can exploratory testing be used for GxP software?
It may be considered when appropriate to the risk and defined objective. For pharmaceutical use, the method should be permitted by the quality system, controlled, recorded, and sufficient to support the intended-use conclusion.
Can a pharma company use supplier testing instead of site testing?
Supplier evidence may be leveraged after the organization evaluates its scope, quality, version, configuration, and relevance. Site-specific intended use, configuration, interfaces, and procedures still need appropriate assurance.
Does 21 CFR Part 11 apply to all electronic records?
No. Assess whether an electronic record is required by FDA regulations or submitted to FDA and whether the organization uses it in place of a paper record or uses an electronic signature in the covered context. Applicable predicate rules remain important.
Does a risk-based approach allow a company to skip testing?
It allows testing to be selected and scaled based on risk; it does not justify omitting evidence without a rationale. Critical functions may need detailed, repeatable testing and strong independent review.
How are CSV and CSA related to EU GMP Annex 11?
Annex 11 is the EU GMP guidance for computerized systems. A company can use risk-based validation and assurance techniques to meet its documented obligations, but it should assess Annex 11 and local procedures directly.
What is the simplest way to start a CSA-informed pharma CSV program?
Begin with an accurate inventory, define intended use and boundaries, perform a function-level risk assessment, reuse relevant supplier evidence, select suitable tests, document decisions, and maintain the system under change and access control.
Conclusion: Use Risk-Based Assurance Without Losing Regulatory Context
CSA and CSV are best understood as related but distinct ideas. CSV provides pharmaceutical organizations with a lifecycle structure for computerized-system control. CSA offers a risk-based way to focus assurance effort, but FDA’s current CSA guidance is written for medical-device production and QMS software. Pharma teams can apply its useful principles—intended-use focus, critical thinking, fit-for-risk testing, and meaningful records—while meeting the GMP and electronic-record requirements that actually apply to their systems.
Primary References
- FDA: Computer Software Assurance for Production and Quality Management System Software — current final guidance page and stated scope.
- FDA: Full CSA Guidance, issued February 3, 2026 — risk framework, assurance activities, and record examples.
- eCFR: 21 CFR Part 11, Electronic Records; Electronic Signatures.
- FDA: Part 11, Electronic Records; Electronic Signatures—Scope and Application.
- eCFR: 21 CFR 211.68, Automatic, Mechanical, and Electronic Equipment.
- European Commission: EudraLex Volume 4 — published EU GMP guidelines and Annex 11 listing.
- ISPE: GAMP 5 Second Edition Table of Contents — lifecycle, verification, operation, and testing topics.
Educational overview only. Apply current regulations, official guidance, approved procedures, and product-specific commitments to the system’s intended use. This article is not a substitute for the full regulations or licensed industry guidance.
.webp)
%20vs%20CSV%20(1).webp&description=Computer Software Assurance (CSA) vs CSV){kind=link}